These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 31464611)

  • 1. Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.
    Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Steuer CE; Wu C; Lawson DH; Kudchadkar R; Master VA; El-Rayes B; Ramalingam SS; Owonikoko TK; Harvey RD
    BMC Cancer; 2019 Aug; 19(1):857. PubMed ID: 31464611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.
    Martini DJ; Liu Y; Shabto JM; Lewis C; Kline MR; Collins H; Akce M; Kissick HT; Carthon BC; Shaib WL; Alese OB; Pillai RN; Steuer CE; Wu CS; Lawson DH; Kudchadkar RR; Master VA; El-Rayes BF; Ramalingam SS; Owonikoko TK; Harvey RD; Bilen MA
    Invest New Drugs; 2019 Dec; 37(6):1198-1206. PubMed ID: 30725388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
    Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
    Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.
    Bilen MA; Martini DJ; Liu Y; Lewis C; Collins HH; Shabto JM; Akce M; Kissick HT; Carthon BC; Shaib WL; Alese OB; Pillai RN; Steuer CE; Wu CS; Lawson DH; Kudchadkar RR; El-Rayes BF; Master VA; Ramalingam SS; Owonikoko TK; Harvey RD
    Cancer; 2019 Jan; 125(1):127-134. PubMed ID: 30329148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.
    Botticelli A; Cirillo A; Scagnoli S; Cerbelli B; Strigari L; Cortellini A; Pizzuti L; Vici P; De Galitiis F; Di Pietro FR; Cerbelli E; Ghidini M; D'Amati G; Della Rocca C; Mezi S; Gelibter A; Giusti R; Cortesi E; Ascierto PA; Nuti M; Marchetti P
    Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32353934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
    Maymani H; Hess K; Groisberg R; Hong DS; Naing A; Piha-Paul S; Janku F; Fu S; Tsimberidou AM; Pant S; Karp D; Liu S; Sun M; Heymach J; Simon G; Meric-Bernstam F; Subbiah V
    Lung Cancer; 2018 Jun; 120():137-141. PubMed ID: 29748008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy.
    Kim SH; Kim JK; Park EY; Joo J; Lee KH; Seo HK; Joung JY; Chung J
    PLoS One; 2019; 14(2):e0211105. PubMed ID: 30785902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
    Wu KL; Tsai MJ; Yang CJ; Chang WA; Hung JY; Yen CJ; Shen CH; Kuo TY; Lee JY; Chou SH; Liu TC; Chong IW; Huang MS
    Lung Cancer; 2015 May; 88(2):187-94. PubMed ID: 25747806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
    Makrakis D; Talukder R; Lin GI; Diamantopoulos LN; Dawsey S; Gupta S; Carril-Ajuria L; Castellano D; de Kouchkovsky I; Koshkin VS; Park JJ; Alva A; Bilen MA; Stewart TF; McKay RR; Tripathi N; Agarwal N; Vather-Wu N; Zakharia Y; Morales-Barrera R; Devitt ME; Cortellini A; Fulgenzi CAM; Pinato DJ; Nelson A; Hoimes CJ; Gupta K; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Murgic J; Fröbe A; Rodriguez-Vida A; Drakaki A; Liu S; Lu E; Kumar V; Lorenzo GD; Joshi M; Isaacsson-Velho P; Buznego LA; Duran I; Moses M; Jang A; Barata P; Sonpavde G; Yu EY; Montgomery RB; Grivas P; Khaki AR
    Clin Genitourin Cancer; 2022 Oct; 20(5):e440-e452. PubMed ID: 35778337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors.
    Shabto JM; Martini DJ; Liu Y; Ravindranathan D; Brown J; Hitron EE; Russler GA; Caulfield S; Kissick H; Alemozaffar M; Ogan K; Harris WB; Master VA; Kucuk O; Carthon BC; Bilen MA
    Cancer Med; 2020 Apr; 9(8):2752-2760. PubMed ID: 32100417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.
    Papadatos-Pastos D; Roda D; De Miguel Luken MJ; Petruckevitch A; Jalil A; Capelan M; Michalarea V; Lima J; Diamantis N; Bhosle J; Molife LR; Banerji U; de Bono JS; Popat S; O'Brien MER; Yap TA
    Eur J Cancer; 2017 Apr; 75():56-62. PubMed ID: 28214659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials.
    Criscitiello C; Marra A; Morganti S; Zagami P; Gandini S; Esposito A; Curigliano G
    Eur J Cancer; 2021 Nov; 157():40-49. PubMed ID: 34474219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
    Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
    Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in 1,521 melanoma patients with distant metastases.
    Barth A; Wanek LA; Morton DL
    J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials.
    Alhalabi O; Hahn AW; Msaouel P; Meric-Bernstam F; Wilson N; Naing A; Piha-Paul S; Janku F; Pant S; Yap TA; Hong DS; Fu S; Karp D; Beltran K; Campbell E; Le H; Campbell MT; Shah A; Tannir NM; Siefker-Radtke A; Gao J; Roszik J; Subbiah V
    Clin Genitourin Cancer; 2022 Feb; 20(1):e16-e24. PubMed ID: 34362693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.
    Garrido-Laguna I; Janku F; Vaklavas C; Falchook GS; Fu S; Hong DS; Naing A; Tsimberidou AM; Wen S; Kurzrock R
    Cancer; 2012 Mar; 118(5):1422-8. PubMed ID: 21823111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer.
    Galli G; Triulzi T; Proto C; Signorelli D; Imbimbo M; Poggi M; Fucà G; Ganzinelli M; Vitali M; Palmieri D; Tessari A; de Braud F; Garassino MC; Colombo MP; Lo Russo G
    Lung Cancer; 2019 Jun; 132():72-78. PubMed ID: 31097097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials.
    Martini DJ; Kline MR; Liu Y; Shabto JM; Williams MA; Khan AI; Lewis C; Collins H; Akce M; Kissick HT; Carthon BC; Shaib WL; Alese OB; Pillai RN; Steuer CE; Wu CS; Lawson DH; Kudchadkar RR; El-Rayes BF; Ramalingam SS; Owonikoko TK; Harvey RD; Master VA; Bilen MA
    Cancer; 2020 Feb; 126(3):575-582. PubMed ID: 31648379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.